Eugia Pharma Receives USFDA Approval for Bortezomib for Injection, 3.5 mg

Eugia Pharma Limited is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Bortezomib for Injection, 3.5 mg.

Indications for this product include:

• Adult patients with multiple myeloma;
• Adult patients with mantle cell lymphoma.

Refer to package insert for full prescribing information.